## Edgar Filing: LANGER DENNIS - Form 4

ANCED DENNIC

Form 4											
June 25, 20	ЛЛ								PPROVAL		
	Washington, D.C. 20549						N OMB Number:	3235-0287			
Check th if no lon subject to Section Form 4 Form 5 obligatio	ger o 16. or Filed put	IENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES suant to Section 16(a) of the Securities Exchange Act of 1934,						Estimated burden hou response	Estimated average burden hours per response 0.8		
may cor See Inst 1(b).	tinue. Section 17(			•	•	npany Act ny Act of 1	of 1935 or Secti 940	on			
(Print or Type	Responses)										
I			2. Issuer Name <b>and</b> Ticker or Trading Symbol Dicerna Pharmaceuticals Inc [DRNA]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
	· · · · ·	C., 87		of Earliest T Day/Year) 2018	ransaction		X Director Officer (giv below)		% Owner her (specify		
			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State)	(Zip)	Tab	le I - Non-I	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if TransactionAcquired (A) or Code Disposed of (D) y/Year) (Instr. 8) (Instr. 3, 4 and 5) (A) or		(A) or of (D) 4 and 5) (A)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Reminder: Re	port on a separate line	e for each cla	uss of sec	urities benef	ficially ow	ned directly o	or indirectly.				

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

## Edgar Filing: LANGER DENNIS - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed o (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 E S (1
				Code V	(A) (D	) Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Director Stock Option (right to buy)	\$ 13.08	06/21/2018		A	25,000	<u>(1)</u>	06/21/2028	Common Stock	25,000	

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
LANGER DENNIS C/O DICERNA PHARMACEUTICAI 87 CAMBRIDGEPARK DRIVE CAMBRIDGE, MA 02140	LS, INC.	X				
Signatures						
/s/ John B. Green, attorney-in-fact	06/25/20	18				
<u>**</u> Signature of Reporting Person	Date					

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This option vests monthly over 12 months from June 21, 2018 ("Grant Date") in substantially equal monthly installments, provided that
 (1) the option will vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through each such date or, if earlier, such annual meeting.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.